Bck Partners, Inc. Amgen Inc Transaction History

Bck Partners, Inc.

$160 Million
Q1 2025

A detailed history of Bck Partners, Inc. transactions in Amgen Inc stock. As of the latest transaction made, Bck Partners, Inc. holds 715 shares of AMGN stock, worth $208,007. This represents 0.14% of its overall portfolio holdings.

Number of Shares

715

Previous 1,054 32.16%

Holding current value

$208,007

Previous $274,000 18.98%

% of portfolio

0.14%

Previous 0.17%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 25, 2025	SELL	$258.59 - $327.36 $87,662 - $110,975	-339 Reduced 32.16%	715 $222,000
Q4 2024 Jan 30, 2025	SELL	$258.78 - $328.31 $5,175 - $6,566	-20 Reduced 1.86%	1,054 $274,000
Q3 2024 Oct 25, 2024	BUY	$309.38 - $337.38 $1,546 - $1,686	5 Added 0.47%	1,074 $346,000
Q2 2024 Jul 24, 2024	BUY	$262.75 - $319.31 $12,349 - $15,007	47 Added 4.6%	1,069 $334,000
Q3 2023 Oct 25, 2023	BUY	$218.65 - $271.46 $223,460 - $277,432	1,022 New	1,022 $274,000
Q4 2022 Jan 20, 2023	SELL	$229.03 - $291.01 $13,970 - $17,751	-61 Reduced 5.53%	1,042 $0
Q1 2022 May 13, 2022	BUY	$219.27 - $242.57 $241,854 - $267,554	1,103 New	1,103 $267,000
Q1 2022 Apr 21, 2022	SELL	$219.27 - $242.57 $246,240 - $272,406	-1,123 Closed	0 $0
Q4 2021 Jan 18, 2022	SELL	$198.88 - $227.6 $38,980 - $44,609	-196 Reduced 14.86%	1,123 $253,000
Q3 2021 Oct 13, 2021	BUY	$212.27 - $248.7 $4,245 - $4,974	20 Added 1.54%	1,319 $280,000
Q1 2021 Apr 28, 2021	BUY	$221.91 - $258.6 $76,337 - $88,958	344 Added 36.02%	1,299 $336,000
Q4 2020 Feb 16, 2021	BUY	$216.38 - $257.67 $206,642 - $246,074	955 New	955 $220,000

Others Institutions Holding AMGN

# of Institutions

3,242

Shares Held

422M

Call Options Held

7.04M

Put Options Held

6.39M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $156B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bck Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Bck Partners, Inc. with notifications on news.

Account